

anti-Cytokeratin (CAM 5.2) Mouse Monoclonal Primary Antibody

REF 790-4555
06478425001

IVD Σ 50




Figure 1. anti-Cytokeratin (CAM 5.2) antibody staining of colon adenocarcinoma.

INTENDED USE

Anti-Cytokeratin (CAM 5.2) Mouse Monoclonal Primary Antibody is intended for laboratory use in the qualitative immunohistochemical detection of cytokeratin 7 (CK7) and cytokeratin 8 (CK8) by light microscopy in sections of formalin-fixed, paraffin-embedded tissue stained on a BenchMark IHC/ISH instrument.

This product should be interpreted by a qualified pathologist in conjunction with histological examination, relevant clinical information, and proper controls.

This antibody is intended for in vitro diagnostic (IVD) use.

SUMMARY AND EXPLANATION

Anti-Cytokeratin (CAM 5.2) Mouse Monoclonal Antibody (anti-Cytokeratin (CAM 5.2) antibody) is a mouse monoclonal antibody that recognizes CK7 and CK8 present in simple epithelia (such as glandular or secretory epithelia).¹⁻⁴ While expression of CK7 is restricted to certain organs, CK8 is one of the earliest cytokeratins expressed during epithelial tissue development.¹⁻⁴ Thus, CK8 is detected in the epithelium of many organs and its expression is typically maintained in the majority of carcinomas including those of the breast, lung, colon, bladder, and thyroid.¹⁻⁴ It has been reported in the literature that the CAM5.2 clone can be used to assist in the identification of carcinomas that may be missed by AE1/AE3 antibodies.^{5,6}

The detection of CK7 and CK8 by immunohistochemistry (IHC) with the anti-Cytokeratin (CAM 5.2) antibody may be used to aid in the identification of neoplasms of epithelial origin. This antibody may be used as part of a panel of IHC studies. The staining pattern is cytoplasmic.

PRINCIPLE OF THE PROCEDURE

Anti-Cytokeratin (CAM 5.2) antibody can be visualized using *ultraView* Universal DAB Detection Kit (Cat. No. 760-500 / 05269806001) or *OptiView* DAB IHC Detection Kit (Cat. No. 760-700 / 06396500001). Refer to the respective method sheet for further information.

MATERIAL PROVIDED

Anti-Cytokeratin (CAM 5.2) antibody contains sufficient reagent for 50 tests.

One 5 mL dispenser of anti-Cytokeratin (CAM 5.2) antibody contains approximately 13 µg of a mouse monoclonal antibody.

The antibody is diluted in Tris-HCl with carrier protein and ProClin 300, a preservative.

Specific antibody concentration is approximately 2.6 µg/mL. There is no known non-specific antibody reactivity observed in this product.

Anti-Cytokeratin (CAM 5.2) antibody is a recombinant monoclonal antibody produced as cell culture supernatant.

Refer to the appropriate VENTANA detection kit method sheet for detailed descriptions of: Principle of the Procedure, Material and Methods, Specimen Collection and Preparation for Analysis, Quality Control Procedures, Troubleshooting, Interpretation of Results, and Limitations.

MATERIALS REQUIRED BUT NOT PROVIDED

Staining reagents, such as VENTANA detection kits and ancillary components, including negative and positive tissue control slides, are not provided.

Not all products listed in the method sheet may be available in all geographies. Consult your local support representative.

The following reagents and materials may be required for staining but are not provided:

1. Recommended control tissue
2. Microscope slides, positively charged
3. Negative Control (Monoclonal) (Cat. No. 760-2014 / 05266670001)
4. *ultraView* Universal DAB Detection Kit (Cat. No. 760-500 / 05269806001)
5. *OptiView* DAB IHC Detection Kit (Cat. No. 760-700 / 06396500001)
6. Protease 1 (Cat. No. 760-2018 / 05266688001)
7. Protease 3 (Cat. No. 760-2020 / 05266718001)
8. EZ Prep Concentrate (10X) (Cat. No. 950-102 / 05279771001)
9. Reaction Buffer Concentrate (10X) (Cat. No. 950-300 / 05353955001)
10. LCS (Predilute) (Cat. No. 650-010 / 05264839001)
11. ULTRA LCS (Predilute) (Cat. No. 650-210 / 05424534001)
12. Cell Conditioning Solution (CC1) (Cat. No. 950-124 / 05279801001)
13. ULTRA Cell Conditioning Solution (ULTRA CC1) (Cat. No. 950-224 / 05424569001)
14. Hematoxylin II (Cat. No. 790-2208 / 05277965001)
15. Bluing Reagent (Cat. No. 760-2037 / 05266769001)
16. General purpose laboratory equipment
17. BenchMark IHC/ISH instrument

STORAGE AND STABILITY

Upon receipt and when not in use, store at 2-8°C. Do not freeze.

To ensure proper reagent delivery and the stability of the antibody, replace the dispenser cap after every use and immediately place the dispenser in the refrigerator in an upright position.

Every antibody dispenser is expiration dated. When properly stored, the reagent is stable to the date indicated on the label. Do not use reagent beyond the expiration date.

SPECIMEN PREPARATION

Routinely processed formalin-fixed, paraffin-embedded (FFPE) tissues are suitable for use with this primary antibody when used with VENTANA detection kits and BenchMark IHC/ISH instruments. The recommended tissue fixative is 10% neutral buffered formalin.⁷ Sections should be cut at approximately 4 µm in thickness and mounted on positively charged slides. Slides should be stained immediately, as antigenicity of cut tissue sections may diminish over time. Ask your Roche representative for a copy of "Recommended Slide Storage and Handling" for more information

It is recommended that positive and negative controls be run simultaneously with unknown specimens.

WARNINGS AND PRECAUTIONS

1. For in vitro diagnostic (IVD) use.
2. For professional use only.
3. Do not use beyond the specified number of tests.
4. ProClin 300 solution is used as a preservative in this reagent. It is classified as an irritant and may cause sensitization through skin contact. Take reasonable precautions when handling. Avoid contact of reagents with eyes, skin, and mucous membranes. Use protective clothing and gloves.
5. Positively charged slides may be susceptible to environmental stresses resulting in inappropriate staining. Ask your Roche representative for more information on how to use these types of slides.
6. Materials of human or animal origin should be handled as biohazardous materials and disposed of with proper precautions. In the event of exposure, the health directives of the responsible authorities should be followed.^{8,9}
7. Avoid contact of reagents with eyes and mucous membranes. If reagents come in contact with sensitive areas, wash with copious amounts of water.
8. Avoid microbial contamination of reagents as it may cause incorrect results.
9. For further information on the use of this device, refer to the BenchMark IHC/ISH instrument User Guide, and instructions for use of all necessary components located at navifyportal.roche.com.
10. Consult local and/or state authorities with regard to recommended method of disposal.
11. Product safety labeling primarily follows EU GHS guidance. Safety data sheet available for professional user on request.

12. To report suspected serious incidents related to this device, contact the local Roche representative and the competent authority of the Member State or Country in which the user is established.

This product contains components classified as follows in accordance with the Regulation (EC) No. 1272/2008:

Table 1. Hazard information.

Hazard	Code	Statement
	H317	May cause an allergic skin reaction.
	H412	Harmful to aquatic life with long lasting effects.
	P261	Avoid breathing mist or vapours.
	P273	Avoid release to the environment.
	P280	Wear protective gloves.
	P333 + P313	If skin irritation or rash occurs: Get medical advice/attention.
	P362 + P364	Take off contaminated clothing and wash it before reuse.
	P501	Dispose of contents/ container to an approved waste disposal plant.

This product contains CAS # 55965-84-9, reaction mass of: 5-chloro-2-methyl-2H-isothiazol-3-one and 2-methyl-2H-isothiazol-3-one (3:1).

STAINING PROCEDURE

VENTANA primary antibodies have been developed for use on BenchMark IHC/ISH instruments in combination with VENTANA detection kits and accessories. Refer to the tables below for recommended staining protocols.

This antibody has been optimized for specific incubation times but the user must validate results obtained with this reagent.

The parameters for the automated procedures can be displayed, printed and edited according to the procedure in the instrument User Guide. Refer to the appropriate VENTANA detection kit method sheet for more details regarding immunohistochemistry staining procedures.

For more details on the proper use of this device, refer to the inline dispenser method sheet associated with P/N 790-4555.

Table 2. Recommended staining protocol for anti-Cytokeratin (CAM 5.2) antibody with *ultraView* Universal DAB Detection Kit on BenchMark IHC/ISH instruments.

Procedure Type	Method	
	GX	ULTRA or ULTRA PLUS ^a
Deparaffinization	Selected	Selected
Cell Conditioning (Antigen Unmasking)	None Required	None Required
Enzyme	Protease 1, 12 minutes	Protease 1, 8 minutes
Antibody (Primary)	20 minutes, 37 °C	16 minutes, 36°C
Counterstain	Hematoxylin II, 4 minutes	
Post Counterstain	Bluing, 4 minutes	

^a Concordance was demonstrated between BenchMark ULTRA and BenchMark ULTRA PLUS instruments using representative assays.

Table 3. Recommended Staining Protocol for anti-Cytokeratin (CAM 5.2) with OptiView DAB IHC Detection Kit on a BenchMark IHC/ISH instruments.

Procedure Type	Method	
	GX	ULTRA or ULTRA PLUS ^a
Deparaffinization	Selected	Selected
Cell Conditioning (Antigen Unmasking)	CC1, 24 minutes	ULTRA CC1 24 minutes, 100 °C
Pre Primary Peroxidase Inhibitor	Selected	
Post Cell Conditioning Enzyme	Protease 3, 4 minutes	Protease 3, 8 minutes
Antibody (Primary)	40 minutes, 37°C	32 minutes, 36 °C
OptiView HQ Linker	8 minutes	
OptiView HRP Multimer	8 minutes	
Counterstain	Hematoxylin II, 4 minutes	
Post Counterstain	Bluing, 4 minutes	

^a Concordance was demonstrated between BenchMark ULTRA and BenchMark ULTRA PLUS instruments using representative assays.

Due to variation in tissue fixation and processing, as well as general lab instrument and environmental conditions, it may be necessary to increase or decrease the primary antibody incubation, cell conditioning or protease pretreatment based on individual specimens, detection used, and reader preference. For further information on fixation variables, refer to "Immunohistochemistry Principles and Advances."¹⁰

NEGATIVE REAGENT CONTROL

In addition to staining with anti-Cytokeratin (CAM 5.2) antibody, a second slide should be stained with the appropriate negative control reagent.

POSITIVE TISSUE CONTROL

Optimal laboratory practice is to include a positive control section on the same slide as the test tissue. This helps identify any failures applying reagents to the slide. Tissue with weak positive staining is best suited for quality control. Control tissue may contain both positive and negative staining elements and serve as both the positive and negative control. Control tissue should be fresh autopsy, biopsy, or surgical specimen, prepared or fixed as soon as possible in a manner identical to test sections.

Known positive tissue controls should be utilized only for monitoring performance of reagents and instruments, not as an aid in determining specific diagnosis of test samples. If the positive tissue controls fail to demonstrate positive staining, results of the test specimen should be considered invalid.

Examples of positive control tissues for this antibody are pancreatic carcinoma and colon.

STAINING INTERPRETATION / EXPECTED RESULTS

The cellular staining pattern for anti-Cytokeratin (CAM 5.2) antibody is cytoplasmic. Cytoplasmic staining of reticulum cells in lymphoid tissues has been observed with CAM 5.2 antibody.¹¹

SPECIFIC LIMITATIONS

This antibody may demonstrate uncharacteristic nuclear staining in brain, bone marrow, and testis. It may also demonstrate uncharacteristic islet cell staining in pancreas and endothelial cell staining in nerve, as well as the smooth muscle tissue of ovary.

OptiView detection system is generally more sensitive than *ultraView* Universal DAB Detection Kit. The user must validate the results obtained with this reagent and detection systems.

All assays might not be registered on every instrument. Please contact your local Roche representative for more information.

PERFORMANCE CHARACTERISTICS

ANALYTICAL PERFORMANCE

Staining tests for sensitivity, specificity, and precision were conducted and the results are listed below.

Sensitivity and Specificity

Table 4. Sensitivity/Specificity of anti-Cytokeratin (CAM 5.2) antibody was determined by testing FFPE non-neoplastic tissues.

Tissue	# positive / total cases	Tissue	# positive / total cases
Cerebrum ^f	0/4	Stomach	4/4
Cerebellum	0/4	Small Intestine	4/4
Spinal Cord	0/2	Colon	6/6
Adrenal gland ^a	4/4	Rectum	4/4
Ovary ^d	1/4	Liver	4/4
Pancreas ^e	9/9	Salivary gland	3/3
Lymph Node ^b	1/1	Kidney ^c	5/5
Parathyroid gland	3/3	Prostate ^a	4/4
Anterior pituitary gland	3/3	Bladder	3/3
Testis ^f	0/4	Ureter	1/1
Thyroid	4/4	Fallopian tube	2/2
Breast	3/3	Endometrium	3/3
Spleen	3/3	Cervix	4/4
Tonsil ^b	2/3	Placenta	3/3
Thymus	3/3	Skeletal muscle	0/3
Bone marrow ^f	0/3	Skin	2/4
Lung	6/6	Nerve ^{g,h}	0/5
Heart	0/3	Mesothelium	3/3
Esophagus	4/4		

^a Tissue evaluated includes normal and hyperplasia

^b Tissue evaluated includes normal and reactive

^c Tissue evaluated includes normal and inflammatory

^d Tissue evaluated includes smooth muscle staining

^e Tissue evaluated includes islet cell staining

^f Tissue evaluated includes nuclear staining

^g Tissue evaluated includes endothelial staining

^h Includes schwannoma tissue

Table 5. Sensitivity/Specificity of anti-Cytokeratin (CAM 5.2) antibody was determined by testing a variety of FFPE neoplastic tissues.

Pathology	# positive / total cases
Meningioma, fibrous (Cerebellum)	0/1
Meningioma, anaplastic (Cerebellum)	0/1
Meningioma, fibrous (Cerebrum)	0/1

Pathology	# positive / total cases
Astrocytoma (Cerebrum)	0/1
Adenocarcinoma (Oral cavity)	1/1
Squamous cell carcinoma (Oral cavity)	1/1
Nasopharyngeal carcinoma (Nasopharynx)	1/1
Adenoma (Adrenal gland)	0/1
Adrenocortical carcinoma (Adrenal gland)	1/1
Granulosa cell tumor (Ovary)	0/1
Adenocarcinoma (Ovary)	1/1
Endometrioid adenocarcinoma (Ovary)	1/1
Metastatic colon signet ring cell carcinoma (Ovary)	1/1
Adenocarcinoma (Pancreas)	64/64
Paraganglioma (Pancreas)	1/1
Cystadenoma (Pancreas)	2/2
Gastrointestinal stromal tumor (GIST) (Pancreas)	1/1
Hemangioma (Pancreas)	1/1
Neuroendocrine Neoplasm (Pancreas)	12/13
Papillary Carcinoma (Pancreas)	1/1
Solid pseudopapillary neoplasm (Pancreas)	1/2
Cystadenocarcinoma (Pancreas)	3/3
Acinar cell carcinoma (Pancreas)	1/1
Undifferentiated carcinoma (Pancreas)	2/2
Metastatic stomach adenocarcinoma (Pancreas)	1/1
Metastatic breast ductal carcinoma (Lymph node)	1/1
Metastatic esophagus squamous cell carcinoma (Lymph Node)	1/1
Seminoma (Testis)	0/1
Adenoma (Parathyroid)	2/2
Adenoma (Thyroid)	3/3
Papillary adenocarcinoma (Thyroid)	2/2
Fibroadenoma (Breast)	2/2
Invasive carcinoma of no special type (Breast)	3/3
Squamous cell carcinoma (Lung)	34/34
Papillary adenocarcinoma (Lung)	5/5
Adenocarcinoma (Lung)	28/28
Adenocarcinoma in-situ (Lung)	1/1
Large cell carcinoma (Lung)	1/1
Small cell carcinoma (Lung)	8/8
Combined small cell carcinoma and squamous cell carcinoma (Lung)	3/3
Metastatic cancer from gastrointestinal site (Lung)	1/1
Adenosquamous carcinoma (Lung)	1/1
Sarcomatoid carcinoma (Lung)	1/1
Squamous cell carcinoma (Esophagus)	2/3
Adenocarcinoma (Stomach)	3/3

Pathology	# positive / total cases
Adenoma (Small intestine)	1/1
Adenocarcinoma (Small intestine)	1/1
Adenoma (Colon)	3/3
Adenocarcinoma (Colon)	96/96
Adenocarcinoma (Rectum)	3/3
Hepatocellular carcinoma (Liver)	4/4
Metastatic colon adenocarcinoma (Liver)	1/1
Pleomorphic adenoma (Salivary gland)	1/1
Adenoid cystic carcinoma (Salivary gland)	1/1
Clear cell carcinoma (Kidney)	2/2
Adenocarcinoma (Prostate)	2/2
Urothelial carcinoma (Bladder)	2/2
Adenocarcinoma (Endometrium)	2/2
Squamous cell carcinoma (Cervix)	1/2
Squamous cell carcinoma (Skin)	1/1
Melanoma (Nasal cavity)	0/1
Hodgkin lymphoma (Lymph node)	1/1
B-cell lymphoma, NOS (Lymph node)	0/1
Anaplastic Large Cell Lymphoma (Lymph node)	0/1
Osteosarcoma (Bone)	0/1
Chondrosarcoma (Bone)	0/1

Precision

Precision studies for anti-Cytokeratin (CAM 5.2) antibody were completed to demonstrate:

- Between lot precision of the antibody.
- Within run and between day precision on a BenchMark ULTRA instrument.
- Between instrument precision on the BenchMark GX, BenchMark ULTRA, and BenchMark ULTRA PLUS instrument.
- Between platform precision between the BenchMark GX, BenchMark ULTRA, and BenchMark ULTRA PLUS instrument.

All studies met their acceptance criteria.

Precision on the BenchMark ULTRA PLUS instrument was demonstrated using representative assays. Studies included Within-run Repeatability, Between-day and Between-run Intermediate Precision. All studies met their acceptance criteria.

CLINICAL PERFORMANCE

Clinical performance data relevant to the intended purpose of anti-Cytokeratin (CAM 5.2) antibody were assessed by systematic review of the literature. The data gathered support the use of the device in accordance with its intended purpose.

REFERENCES

1. Dabbs DJ. Diagnostic Immunohistochemistry: Theranostic and Genomic Applications, 5th Edition. Amsterdam, Netherlands: Elsevier; 2018.
2. Karantza V. Keratins in Health and Cancer: More Than Mere Epithelial Cell Markers. *Oncogene*. 2011;30(2):127-138.
3. Chu PG, Weiss LM. Keratin Expression in Human Tissues and Neoplasms. *Histopathology*. 2002;40(5):403-439.
4. Moll R, Divo M, Langbein L. The Human Keratins: Biology and Pathology. *Histochem Cell Biol*. 2008;129(6):705-733.
5. Bahrami A, Truong LD, Ro JY. Undifferentiated Tumor: True Identity by Immunohistochemistry. *Arch Pathol Lab Med*. 2008;132(3):326-348.

6. Ordonez NG. Broad-Spectrum Immunohistochemical Epithelial Markers: A Review. *Hum Pathol*. 2013;44(7):1195-1215.
7. Carson FL, Cappellano C. *Histotechnology; A Self-Instructional Text*, 5th edition. American Society for Clinical Pathology Press; 2020, 2022.
8. Occupational Safety and Health Standards: Occupational exposure to hazardous chemicals in laboratories. (29 CFR Part 1910.1450). Fed. Register.
9. Directive 2000/54/EC of the European Parliament and Council of 24 June 2020 on the protection of workers from risks related to exposure to biological agents at work.
10. Roche PC, Hsi ED. *Immunohistochemistry-Principles and Advances*. Manual of Clinical Laboratory Immunology, 6th edition. In: NR Rose, ed. ASM Press; 2002.
11. Linden MD, Zarbo RJ. Cytokeratin Immunostaining Patterns of Benign, Reactive Lymph Nodes: Applications for the Evaluation of Sentinel Lymph Node Specimens. *Appl Immunohistochem Mol Morphol*. 2001;9(4):297-301.

NOTE: A point (period/stop) is always used in this document as the decimal separator to mark the border between the integral and the fractional parts of a decimal numeral. Separators for thousands are not used.

The summary of safety and performance can be found here:

<https://ec.europa.eu/tools/eudamed>

Symbols

Ventana uses the following symbols and signs in addition to those listed in the ISO 15223-1 standard (for USA: see elabdoc.roche.com/symbols for more information).



Global Trade Item Number

Rx only

For USA: Caution: Federal law restricts this device to sale by or on the order of a physician.

REVISION HISTORY

Rev	Updates
J	Includes updates to the Principle of the Procedure, Material Provided, Materials Required but not Provided, Staining Procedure, Specific Limitations, and Performance Characteristics sections.

INTELLECTUAL PROPERTY

VENTANA, BENCHMARK, ULTRAVIEW, and OPTIVIEW are trademarks of Roche. All other product names and trademarks are the property of their respective owners. © 2025 Ventana Medical Systems, Inc.

For USA: Rx only

CONTACT INFORMATION



Ventana Medical Systems, Inc.
1910 E. Innovation Park Drive
Tucson, AZ 85755
USA
+1 520 887 2155
+1 800 227 2155 (USA)

www.roche.com



Roche Diagnostics GmbH
Sandhofer Strasse 116
68305 Mannheim
Germany
+800 5505 6606

